Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean M Wingerchuk

Showing results (171-180 of 184) with videos related to

Pageof 19
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|April 7, 2017
Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter studyRiley Bove, Liene Elsone, Enrique Alvarez, et al.
Annals of Neurology|February 19, 2016
Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrumEoin P Flanagan, Philippe Cabre, Brian G Weinshenker, et al.
The Lancet. Neurology|May 17, 2024
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trialBruce A C Cree, Ho Jin Kim, Brian G Weinshenker, et al.
Neurology|June 21, 2015
International consensus diagnostic criteria for neuromyelitis optica spectrum disordersDean M Wingerchuk, Brenda Banwell, Jeffrey L Bennett, et al.
Neurology|December 16, 2014
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesionsBogdan F G Popescu, Yong Guo, Mark E Jentoft, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentumBrian G Weinshenker, Dean M Wingerchuk, Ari J Green, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Sean J Pittock, Friedemann Paul, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 9, 2026
Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSDMoritz Niederschweiberer, Cicek Bakir, Nisa Vorasoot, et al.
Lancet (London, England)|September 10, 2019
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Neurology|April 5, 2015
Challenges and opportunities in designing clinical trials for neuromyelitis opticaBrian G Weinshenker, Gerard Barron, Jacinta M Behne, et al.
Pageof 19

Showing results (171-180 of 184) with videos related to

Sort By:
Pageof 19
Neurology(R) Neuroimmunology & Neuroinflammation|April 7, 2017
Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter studyRiley Bove, Liene Elsone, Enrique Alvarez, et al.
Annals of Neurology|February 19, 2016
Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrumEoin P Flanagan, Philippe Cabre, Brian G Weinshenker, et al.
The Lancet. Neurology|May 17, 2024
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trialBruce A C Cree, Ho Jin Kim, Brian G Weinshenker, et al.
Neurology|June 21, 2015
International consensus diagnostic criteria for neuromyelitis optica spectrum disordersDean M Wingerchuk, Brenda Banwell, Jeffrey L Bennett, et al.
Neurology|December 16, 2014
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesionsBogdan F G Popescu, Yong Guo, Mark E Jentoft, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentumBrian G Weinshenker, Dean M Wingerchuk, Ari J Green, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Sean J Pittock, Friedemann Paul, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 9, 2026
Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSDMoritz Niederschweiberer, Cicek Bakir, Nisa Vorasoot, et al.
Lancet (London, England)|September 10, 2019
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Neurology|April 5, 2015
Challenges and opportunities in designing clinical trials for neuromyelitis opticaBrian G Weinshenker, Gerard Barron, Jacinta M Behne, et al.
Pageof 19